Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial
Conclusion:
In PLHIV, statins prescribed at a lower threshold than guidelines did not lead to improvements in CIMT but was associated with significant adverse events.
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE: CONCISE COMMUNICATION Source Type: research
More News: Australia Health | Cardiology | Cardiovascular | Cholesterol | Crestor | Heart | HIV AIDS | Infectious Diseases | Norvir | Rosuvastatin | Science | Statin Therapy | Study | Switzerland Health